GGrantIndex
← Leaderboards

Malcolm A Leissring

Brigham And Women'S Hospital

$5,920,046
Attributed
$5,920,046
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $789.8K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,920,046 · 7

By mechanism

R01$4,355,151 · 2
R21$1,539,895 · 4
R03$25,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposPeptide HydrolasesLeadCellsS DiseaseProteinsExtracellularCerebrumMutationPathogenesisInsulinaseBaseInnovationAmyloidExperimental StudyInsightS Disease RiskInterestBlood - Brain Barrier AnatomyDefectInhibitor/AntagonistAmyloid Beta-ProteinGeneticAnimal Model

Grant awards (19)

Temporal and spatial aspects of amyloidogenesis in sporadic Alzheimer disease$541,947
R01 · FY2025 · AG · contact PI
Temporal and spatial aspects of amyloidogenesis in sporadic Alzheimer disease$622,244
R01 · FY2024 · AG · contact PI
Temporal and spatial aspects of amyloidogenesis in sporadic Alzheimer disease$626,169
R01 · FY2023 · AG · contact PI
Temporal and spatial aspects of amyloidogenesis in sporadic Alzheimer disease$543,137
R01 · FY2022 · AG · contact PI
A single-molecule protein nanocapsule for targeted delivery of diverse cargo$231,375
R21 · FY2022 · GM · contact PI
Temporal and spatial aspects of amyloidogenesis in sporadic Alzheimer disease$583,548
R01 · FY2021 · AG · contact PI
A single-molecule protein nanocapsule for targeted delivery of diverse cargo$206,216
R21 · FY2021 · GM · contact PI
Zinc-targeting inhibitors of insulin-degrading enzyme$286,100
R01 · FY2020 · GM · contact PI
Zinc-targeting inhibitors of insulin-degrading enzyme$286,916
R01 · FY2019 · GM · contact PI
Zinc-targeting inhibitors of insulin-degrading enzyme$287,675
R01 · FY2018 · GM · contact PI
Transient defects in Abeta catabolism in the etiology of sporadic Alzheimer disease$193,125
R21 · FY2018 · AG · contact PI
Zinc-targeting inhibitors of insulin-degrading enzyme$288,380
R01 · FY2017 · GM · contact PI
Transient defects in Abeta catabolism in the etiology of sporadic Alzheimer disease$231,750
R21 · FY2017 · AG · contact PI
Zinc-targeting inhibitors of insulin-degrading enzyme$289,035
R01 · FY2016 · GM · contact PI
High-throughput compound screening for modulators of insulin-degrading enzyme.$188,190
R21 · FY2009 · AG · contact PI
High-throughput compound screening for modulators of insulin-degrading enzyme.$156,825
R21 · FY2008 · AG · contact PI
HTS for Modulators of Beta-Amyloid Catabolism by Insulin-Degrading Enzyme$25,000
R03 · FY2007 · DA · contact PI
Peripheral Degradation of Amyloid Beta-Protein$166,352
R21 · FY2006 · AG · contact PI
Peripheral Degradation of Amyloid Beta-Protein$166,062
R21 · FY2005 · AG